JP2019516693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516693A5 JP2019516693A5 JP2018559186A JP2018559186A JP2019516693A5 JP 2019516693 A5 JP2019516693 A5 JP 2019516693A5 JP 2018559186 A JP2018559186 A JP 2018559186A JP 2018559186 A JP2018559186 A JP 2018559186A JP 2019516693 A5 JP2019516693 A5 JP 2019516693A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human patient
- administration
- prior
- neoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 55
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 52
- 229960004768 irinotecan Drugs 0.000 claims description 49
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 36
- 229940034982 antineoplastic agent Drugs 0.000 claims description 32
- 238000002560 therapeutic procedure Methods 0.000 claims description 31
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 28
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 25
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 25
- 229910052697 platinum Inorganic materials 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 229940109239 creatinine Drugs 0.000 claims description 14
- 239000007972 injectable composition Substances 0.000 claims description 13
- 239000002502 liposome Substances 0.000 claims description 13
- 239000002111 antiemetic agent Substances 0.000 claims description 11
- 229940125683 antiemetic agent Drugs 0.000 claims description 11
- 239000012458 free base Substances 0.000 claims description 10
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 7
- 102000001554 Hemoglobins Human genes 0.000 claims description 7
- 108010054147 Hemoglobins Proteins 0.000 claims description 7
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 7
- 210000001772 blood platelet Anatomy 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 7
- 229960004316 cisplatin Drugs 0.000 claims description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- 239000008355 dextrose injection Substances 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000003394 haemopoietic effect Effects 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000008354 sodium chloride injection Substances 0.000 claims description 7
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 12
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 239000003246 corticosteroid Substances 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 4
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical class OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 239000006185 dispersion Substances 0.000 description 6
- 190000008236 carboplatin Chemical compound 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US62/337,961 | 2016-05-18 | ||
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US62/345,178 | 2016-06-03 | ||
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US62/362,735 | 2016-07-15 | ||
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US62/370,449 | 2016-08-03 | ||
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US62/394,870 | 2016-09-15 | ||
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US62/414,050 | 2016-10-28 | ||
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US62/415,821 | 2016-11-01 | ||
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US62/422,807 | 2016-11-16 | ||
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US62/433,925 | 2016-12-14 | ||
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US62/455,823 | 2017-02-07 | ||
| US201762474661P | 2017-03-22 | 2017-03-22 | |
| US62/474,661 | 2017-03-22 | ||
| PCT/IB2017/000681 WO2017199093A1 (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085131A Division JP2020117548A (ja) | 2016-05-18 | 2020-05-14 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516693A JP2019516693A (ja) | 2019-06-20 |
| JP2019516693A5 true JP2019516693A5 (enExample) | 2020-06-25 |
Family
ID=59258274
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559186A Withdrawn JP2019516693A (ja) | 2016-05-18 | 2017-05-17 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
| JP2020085131A Withdrawn JP2020117548A (ja) | 2016-05-18 | 2020-05-14 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
| JP2021185609A Pending JP2022010295A (ja) | 2016-05-18 | 2021-11-15 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085131A Withdrawn JP2020117548A (ja) | 2016-05-18 | 2020-05-14 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
| JP2021185609A Pending JP2022010295A (ja) | 2016-05-18 | 2021-11-15 | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (enExample) |
| EP (1) | EP3458059A1 (enExample) |
| JP (3) | JP2019516693A (enExample) |
| KR (1) | KR20190009319A (enExample) |
| CN (1) | CN109640995A (enExample) |
| AU (1) | AU2017267449A1 (enExample) |
| BR (1) | BR112018072988A2 (enExample) |
| CA (1) | CA3023743A1 (enExample) |
| IL (1) | IL262656A (enExample) |
| MA (1) | MA45046A (enExample) |
| MX (1) | MX394766B (enExample) |
| PH (1) | PH12018502422A1 (enExample) |
| SG (2) | SG10201912407YA (enExample) |
| TW (1) | TWI791437B (enExample) |
| UA (1) | UA125646C2 (enExample) |
| WO (1) | WO2017199093A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| IL257149B2 (en) | 2015-08-21 | 2024-11-01 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| MX382522B (es) | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA86063C2 (ru) * | 2004-05-03 | 2009-03-25 | Хермес Біосайенсез, Інк. | Липосомы для снабжения лекарств |
| ES2550759T3 (es) * | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 MX MX2018013873A patent/MX394766B/es unknown
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Ceased
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en not_active Ceased
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516693A5 (enExample) | ||
| Ickenstein et al. | Lipid-based nanoparticle formulations for small molecules and RNA drugs | |
| ES2704986T3 (es) | Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab | |
| FI3821887T3 (fi) | Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon | |
| JP2015523355A5 (enExample) | ||
| ES2301871T3 (es) | Corticosteroides encapsulados en vesiculas para el tratamiento del cancer. | |
| TWI362931B (en) | Irinotecan formulation | |
| TWI749091B (zh) | 脂質體調配物 | |
| PT2508207E (pt) | Nanopartículas carregadas com um medicamento antitumoral quimioterapêutico | |
| CN101522172A (zh) | 癌症治疗 | |
| US20190343766A1 (en) | Medical use of spla2 hydrolysable liposomes | |
| US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| TWI791437B (zh) | 以微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）治療小細胞肺癌 | |
| JP2016513651A5 (enExample) | ||
| BR112014018393B1 (pt) | Composição farmacêutica adequada para liberação ocular de um esteroide e uso da mesma para a fabricação de um medicamento para tratar uma doença oftálmica | |
| JP2014532697A (ja) | ヒトにおける炎症性障害の治療用リポソームコルチコステロイド | |
| JP2017537124A5 (enExample) | ||
| US10617672B2 (en) | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | |
| JP2008540364A (ja) | パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法 | |
| US20020110601A1 (en) | Antineoplastic platinum therapeutic method and composition | |
| ES3058285T3 (en) | Pharmaceutical compositions with reduced side effect and methods of using the same | |
| TW202320802A (zh) | Ｂｃｌ抑制劑之脂質體調配物 | |
| PT1781255E (pt) | Composições e métodos para tratamento da leucemia | |
| JP2020521004A (ja) | ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム | |
| KR20250093579A (ko) | 관절내 스테로이드의 합병증을 감소시키는 방법 |